Supriya Lifescience Ltd
₹655
(-1.15%)
Mon, 02 Mar 2026, 07:57 am
Health Technology
Pharmaceuticals: Major
24.5KSupriya Lifescience Debt to Equity Ratio
| Particulars | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 26.13 | 17.08 | 22.42 | 31.41 |
| Price to book ratio | 0 | 0 | 0 | 0 | 6.44 | 2.19 | 3.27 | 5.92 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 7.63 | 3.41 | 4.79 | 8.69 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 75.98 | 21.14 | 21.65 | 34.21 |
| Enterprise value | 0 | 0 | 0 | 0 | 37.67B | 14B | 26.01B | 58.3B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 17.89 | 10.99 | 15.35 | 22.85 |
| Debt to equity ratio | 2.39 | 0.98 | 0.57 | 0.27 | 0.04 | 0.03 | 0.01 | 0.01 |
| Return on equity % | 0 | 53.11 | 60.40 | 59.17 | 34.34 | 13.66 | 15.73 | 20.74 |
Supriya Lifescience Ltd Debt to Equity Ratio
The Supriya Lifescience Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Supriya Lifescience Ltd's valuation, profitability, and overall financial performance. Tracking the Supriya Lifescience Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Supriya Lifescience Ltd (NSE: SUPRIYA, BSE: 543434) is currently trading at ₹655, with a market capitalization of ₹52.58B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Supriya Lifescience Ltd Debt to Equity Ratio is essential for fundamental analysis.
Supriya Lifescience Ltd Debt to Equity Ratio Current Value
The current Supriya Lifescience Ltd Debt to Equity Ratio stands at 0.01.
The Supriya Lifescience Ltd Debt to Equity Ratio remains stable, indicating consistent financial performance.
Supriya Lifescience Ltd Debt to Equity Ratio Historical Trend
The Supriya Lifescience Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.01
- 2023: 0.01
- 2022: 0.03
- 2021: 0.04
- 2020: 0.27
The decline in Supriya Lifescience Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What Supriya Lifescience Ltd Debt to Equity Ratio Indicates for Investors
The Supriya Lifescience Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Supriya Lifescience Ltd Debt to Equity Ratio Analysis Summary
The Supriya Lifescience Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Supriya Lifescience Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Supriya Lifescience Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800